AU2018311128A1 - Treatment of local skin hypotrophy conditions - Google Patents

Treatment of local skin hypotrophy conditions Download PDF

Info

Publication number
AU2018311128A1
AU2018311128A1 AU2018311128A AU2018311128A AU2018311128A1 AU 2018311128 A1 AU2018311128 A1 AU 2018311128A1 AU 2018311128 A AU2018311128 A AU 2018311128A AU 2018311128 A AU2018311128 A AU 2018311128A AU 2018311128 A1 AU2018311128 A1 AU 2018311128A1
Authority
AU
Australia
Prior art keywords
mrna
fgf2
fgf7
fgf
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018311128A
Other languages
English (en)
Inventor
Markus Mandler
Frank Mattner
Walter Schmidt
Achim Schneeberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accanis Biotech F&e & Co KG GmbH
Original Assignee
Accanis Biotech F&e & Co KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accanis Biotech F&e & Co KG GmbH filed Critical Accanis Biotech F&e & Co KG GmbH
Publication of AU2018311128A1 publication Critical patent/AU2018311128A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018311128A 2017-07-31 2018-07-31 Treatment of local skin hypotrophy conditions Abandoned AU2018311128A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183990.5A EP3437650A1 (en) 2017-07-31 2017-07-31 Treatment of local skin hypotrophy conditions
EP17183990.5 2017-07-31
PCT/EP2018/070712 WO2019025431A1 (en) 2017-07-31 2018-07-31 TREATMENT OF LOCAL SKIN HYPOTROPHIC CONDITIONS

Publications (1)

Publication Number Publication Date
AU2018311128A1 true AU2018311128A1 (en) 2020-02-06

Family

ID=59506101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018311128A Abandoned AU2018311128A1 (en) 2017-07-31 2018-07-31 Treatment of local skin hypotrophy conditions

Country Status (8)

Country Link
US (1) US20200369738A1 (https=)
EP (2) EP3437650A1 (https=)
JP (2) JP2020529208A (https=)
KR (1) KR20200035073A (https=)
CN (1) CN111050785A (https=)
AU (1) AU2018311128A1 (https=)
CA (1) CA3070880A1 (https=)
WO (1) WO2019025431A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012683A (es) * 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
US20220015986A1 (en) * 2020-07-16 2022-01-20 Hillary Hayman Three-step process for mimicking plastic surgery results
CN114717230B (zh) * 2021-01-05 2024-09-03 麦塞拿治疗(香港)有限公司 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF
KR102432810B1 (ko) * 2021-10-29 2022-08-16 주식회사 엣지케어 약물전달 시스템 및 약물전달 시스템의 동작방법
WO2024151673A2 (en) * 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
CN120137909A (zh) * 2025-03-12 2025-06-13 广州酷奇圈科研与推广应用有限公司 重组外泌体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1168997B1 (en) 1999-04-02 2013-04-24 KCI Licensing, Inc. Vacuum assisted closure system with provision for introduction of agent
US7202226B2 (en) * 2000-10-23 2007-04-10 Detroit R & D Augmentation of wound healing by elF-4E mRNA and EGF mRNA
KR20060123256A (ko) * 2003-11-11 2006-12-01 가부시키가이샤 시세이도 모발의 태모화 방법 및 조성물
US7816140B2 (en) 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
RU2008128451A (ru) * 2005-12-14 2010-01-20 Огенодженесис, Инк. (US) Композиция для лечения и ухода за кожей, способ ее получения, способ ее использования
US20100143289A1 (en) 2006-12-19 2010-06-10 Michael Cohen Umbilical cord stem cell secreted product derived topical compositions and methods of use thereof
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2009119073A1 (ja) * 2008-03-28 2009-10-01 北海道公立大学法人札幌医科大学 皮膚の老化や瘢痕の治療剤
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
US8759287B2 (en) 2011-04-12 2014-06-24 M-3 Biologics, Llc Methods of decreasing incisional hernia formation and acute wound failure in obese patients by administering basic fibroblast growth factor
WO2013002331A1 (ja) * 2011-06-28 2013-01-03 株式会社バイオセレンタック 皮膚治療用微細針集積型製剤
US9439940B2 (en) 2011-07-19 2016-09-13 Neville Pharmaceutical, Inc. Topical transdermal method for delivering nutrients through the skin for expeditied wound healing and skin rejuvenation
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
EP3099801B1 (en) * 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
WO2016100820A2 (en) 2014-12-19 2016-06-23 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Also Published As

Publication number Publication date
EP3661540A1 (en) 2020-06-10
JP2023145532A (ja) 2023-10-11
CA3070880A1 (en) 2019-02-07
JP2020529208A (ja) 2020-10-08
CN111050785A (zh) 2020-04-21
WO2019025431A1 (en) 2019-02-07
EP3437650A1 (en) 2019-02-06
US20200369738A1 (en) 2020-11-26
KR20200035073A (ko) 2020-04-01

Similar Documents

Publication Publication Date Title
US20200369738A1 (en) Treatment of Local Skin Hypotrophy Conditions
Frazier et al. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor
Chereddy et al. Combined effects of PLGA and vascular endothelial growth factor promote the healing of non-diabetic and diabetic wounds
EP0703979B1 (en) Method for treating kaposi's sarcoma with antisense oligonucleotides
US9782429B2 (en) Formulation having mobilizing activity
US9321821B2 (en) Cosmetic composition for improving skin conditions comprising fusion protein
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
EP4019037A1 (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
KR20100124820A (ko) 합성 포스포디에스테르 올리고뉴클레오타이드 및 이들의 치료적 용도
US20240399032A1 (en) Hydrogel for promoting growth of mesenchymal stem cells, and preparation method and application method thereof
CN107982536B (zh) 一种药物作用靶点的组合物和应用
Zhao et al. Delayed wound healing in the elderly and a new therapeutic target: CD271
LU603935B1 (en) In Vivo Self-Assembled Central Nervous System-Targeting System for Treating Diabetes
US11890322B2 (en) Methods for promoting wound healing and hair growth comprising GDNF administration
EP1671655A1 (en) Gene therapy for skin diseases using needle free syringe
Tchorzewski et al. Characterization of an aFGF gene expression vector with therapeutic potential
EP4374870A1 (en) Codon-optimized oligonucleotide for induction of elastin de-novo synthesis in mammals
US9371523B2 (en) Cell migration regulator
HK40067000A (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
JP2002524468A (ja) プロサポシン受容体活性を刺激する方法
TW202328443A (zh) 一種生產具高生理穩定性與高效能二聚體之單鏈ｖｅｇｆ融合蛋白的核酸載體及其製備方法和用途
JP2011084569A (ja) プロサポシン受容体活性を刺激する方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application